Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Recurrence 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Stomach Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1Melanoma 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lymphatic Diseases 1Immunoproliferative Disorders 1Immune System Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Brain Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Temozolomide 162Radiosurgery 114Radiotherapy 99Bevacizumab 95Magnetic Resonance Spectroscopy 64Carboplatin 48Etoposide 34Surgical Procedures, Operative 33Irinotecan 33pembrolizumab 32Nivolumab 32Cyclophosphamide 32Erlotinib Hydrochloride 31Radiation 29Carmustine 28Cisplatin 25Lomustine 24Trastuzumab 23Ipilimumab 23Filgrastim 23Vincristine 20Mental Status and Dementia Tests 20Aminolevulinic Acid 19Topotecan 18Pemetrexed 18Capecitabine 18Specimen Handling 17Sorafenib 15Radiotherapy, Intensity-Modulated 15Imatinib Mesylate 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Brain Neoplasms × CA-4948 × Clear all
NCT05669352 2025-04-04

A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases

University of Florida

Phase 1/2 Suspended
29 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡